AUPN861496A0 - Lytic peptides - Google Patents

Lytic peptides

Info

Publication number
AUPN861496A0
AUPN861496A0 AUPN8614A AUPN861496A AUPN861496A0 AU PN861496 A0 AUPN861496 A0 AU PN861496A0 AU PN8614 A AUPN8614 A AU PN8614A AU PN861496 A AUPN861496 A AU PN861496A AU PN861496 A0 AUPN861496 A0 AU PN861496A0
Authority
AU
Australia
Prior art keywords
lytic peptides
lytic
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPN8614A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commonwealth Scientific and Industrial Research Organization CSIRO
Original Assignee
Commonwealth Scientific and Industrial Research Organization CSIRO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commonwealth Scientific and Industrial Research Organization CSIRO filed Critical Commonwealth Scientific and Industrial Research Organization CSIRO
Priority to AUPN8614A priority Critical patent/AUPN861496A0/en
Publication of AUPN861496A0 publication Critical patent/AUPN861496A0/en
Priority to NZ331771A priority patent/NZ331771A/en
Priority to ZA9702186A priority patent/ZA972186B/en
Priority to CA002248782A priority patent/CA2248782A1/en
Priority to EP97906936A priority patent/EP0901502A4/en
Priority to PCT/AU1997/000160 priority patent/WO1997033908A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43572—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from bees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AUPN8614A 1996-03-13 1996-03-13 Lytic peptides Abandoned AUPN861496A0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AUPN8614A AUPN861496A0 (en) 1996-03-13 1996-03-13 Lytic peptides
NZ331771A NZ331771A (en) 1996-03-13 1997-03-13 Lytic peptides with amphipathic alpha helices and positively charged N- or C-terminal, methods of activation/inactivation, compositions and methods of treatment are also included
ZA9702186A ZA972186B (en) 1996-03-13 1997-03-13 Lytic peptides.
CA002248782A CA2248782A1 (en) 1996-03-13 1997-03-13 Lytic peptides
EP97906936A EP0901502A4 (en) 1996-03-13 1997-03-13 Lytic peptides
PCT/AU1997/000160 WO1997033908A1 (en) 1996-03-13 1997-03-13 Lytic peptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPN8614A AUPN861496A0 (en) 1996-03-13 1996-03-13 Lytic peptides

Publications (1)

Publication Number Publication Date
AUPN861496A0 true AUPN861496A0 (en) 1996-04-04

Family

ID=3792926

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPN8614A Abandoned AUPN861496A0 (en) 1996-03-13 1996-03-13 Lytic peptides

Country Status (6)

Country Link
EP (1) EP0901502A4 (en)
AU (1) AUPN861496A0 (en)
CA (1) CA2248782A1 (en)
NZ (1) NZ331771A (en)
WO (1) WO1997033908A1 (en)
ZA (1) ZA972186B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9705519D0 (en) * 1997-03-18 1997-05-07 Anmat Technology Limited Activation of peptides
EP1093519A2 (en) * 1998-07-09 2001-04-25 The University Of Southern California Amphiphilic peptides derived from the cytoplasmic tail of viral envelope proteins
WO2000018895A1 (en) 1998-09-25 2000-04-06 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
AU1394500A (en) * 1998-11-18 2000-06-05 Innature Limited Product
GB9926875D0 (en) 1999-11-12 2000-01-12 Microbiological Research Agenc Use of lytic toxins and toxin conjugates
EP1282642B1 (en) 2000-05-09 2006-09-06 Greenville Hospital System Therapeutic pore-forming peptides
DE60329382D1 (en) 2002-04-22 2009-11-05 Dow Global Technologies Inc COST-EFFECTIVE PRODUCTION OF PEPTIDES
ES2548767T3 (en) 2007-01-16 2015-10-20 The Regents Of The University Of California New antimicrobial peptides
WO2009102859A2 (en) 2008-02-14 2009-08-20 3M Innovative Properties Company Polypeptides for microbial detection
WO2014070957A1 (en) * 2012-10-30 2014-05-08 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5645996A (en) * 1994-08-24 1997-07-08 Torrey Pines Institute For Molecular Studies Melittin-related polypeptides, mixture sets and libraries thereof

Also Published As

Publication number Publication date
ZA972186B (en) 1997-11-10
WO1997033908A1 (en) 1997-09-18
CA2248782A1 (en) 1997-09-18
EP0901502A1 (en) 1999-03-17
NZ331771A (en) 2000-04-28
EP0901502A4 (en) 2001-09-26

Similar Documents

Publication Publication Date Title
AU4922497A (en) Interleukin-18-receptor proteins
AU1847497A (en) Protein expression system
AU6721696A (en) Cd44-like protein
AU2972097A (en) Peptide derivatives
ZA9710338B (en) Proteins
AU4394396A (en) Modified peptides
AU1803597A (en) Peptide derivatives
AU2131195A (en) Prophenins - antibiotic peptides
AUPO026596A0 (en) Viral peptide
AUPN861496A0 (en) Lytic peptides
AU4967397A (en) Water-soluble peptides
AU5061698A (en) Peptide derivatives
AU1999999A (en) Contryphan peptides
AU4401997A (en) Mannosylated peptides
AUPO366496A0 (en) Collagen preparations
AU5764898A (en) Multiple branch peptide constructions
AUPM489194A0 (en) Peptides
AU5161296A (en) Anti-haemorrhagic peptides
AUPO324096A0 (en) Linker peptide
AU6476398A (en) Novel peptides
AU5137598A (en) Novel protein
GB9613705D0 (en) Novel peptides
AUPN159695A0 (en) Lytic peptides
AUPO061096A0 (en) Novel peptides
AUPO383096A0 (en) Novel peptides